These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 33487183)

  • 41. Immunisation practices of paediatric oncology and shared care oncology consultants: a United Kingdom survey.
    Bate J; Patel SR; Chisholm J; Heath PT;
    Pediatr Blood Cancer; 2010 Jul; 54(7):941-6. PubMed ID: 20162684
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Randomized Controlled Trial Using Automated Technology for Improving Ototoxicity Monitoring in VA Oncology Patients.
    Konrad-Martin D; O'Connell Bennett K; Garinis A; McMillan GP
    Am J Audiol; 2021 Oct; 30(3S):870-886. PubMed ID: 34582263
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.
    Langer T; Clemens E; Broer L; Maier L; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Mayer B; von dem Knesebeck A; Byrne J; van Dulmen-den Broeder E; Crocco M; Grabow D; Kaatsch P; Kaiser M; Spix C; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Bielack S; Sorg B; Hecker-Nolting S; Kuehni CE; Ansari M; Kompis M; van der Pal H; Parfitt R; Deuster D; Matulat P; Tillmanns A; Tissing WJE; Beck JD; Elsner S; Am Zehnhoff-Dinnesen A; van den Heuvel-Eibrink MM; Zolk O;
    Eur J Cancer; 2020 Oct; 138():212-224. PubMed ID: 32905960
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cisplatin-associated ototoxicity: perspectives from a single institution cervical cancer cohort and implications for developing a locally responsive monitoring programme in a public healthcare setting.
    Paken J; Govender CD; Pillay M; Sewram V
    BMC Health Serv Res; 2022 Jun; 22(1):791. PubMed ID: 35717191
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2016 Sep; 9(9):CD009219. PubMed ID: 27669661
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ["Let the cobbler stick to his last"].
    Brunner M
    HNO; 2007 Apr; 55(4):241-4; discussion 244. PubMed ID: 17357788
    [No Abstract]   [Full Text] [Related]  

  • 47. Current sedation practices in paediatric audiology clinics in gauteng, South Africa.
    Khoza-Shangase K
    Int J Pediatr Otorhinolaryngol; 2019 Jul; 122():93-98. PubMed ID: 30991207
    [TBL] [Abstract][Full Text] [Related]  

  • 48. COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.
    Crabb SJ; Martin K; Abab J; Ratcliffe I; Thornton R; Lineton B; Ellis M; Moody R; Stanton L; Galanopoulou A; Maishman T; Geldart T; Bayne M; Davies J; Lamb C; Popat S; Joffe JK; Nutting C; Chester J; Hartley A; Thomas G; Ottensmeier C; Huddart R; King E
    Eur J Cancer; 2017 Dec; 87():75-83. PubMed ID: 29128692
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Incidence and associated risk factors for platinum-induced ototoxicity in pediatric patients.
    Waissbluth S; Del Valle Á; Chuang A; Becker A
    Int J Pediatr Otorhinolaryngol; 2018 Aug; 111():174-179. PubMed ID: 29958605
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
    Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
    Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Latest trends in the assessment and management of paediatric snoring and sleep apnoea.
    Sharma SD; Kanona H; Kumar G; Kotecha B
    J Laryngol Otol; 2016 May; 130(5):482-9. PubMed ID: 27095553
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hearing loss related to ototoxicity in children with cancer.
    Landier W
    J Pediatr Oncol Nurs; 1998 Oct; 15(4):195-206. PubMed ID: 9810786
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The use of blood products in paediatric oncology units in the UK.
    Nathan M; Selwood K;
    Paediatr Nurs; 2006 Sep; 18(7):14-7. PubMed ID: 16986749
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The impact of chemotherapy-induced inner ear damage on quality of life in cancer survivors: a qualitative study.
    Pearson SE; Caimino C; Shabbir M; Baguley DM
    J Cancer Surviv; 2022 Oct; 16(5):976-987. PubMed ID: 34398361
    [TBL] [Abstract][Full Text] [Related]  

  • 55. What Are the Current Audiological Practices for Ototoxicity Assessment and Management in the South African Healthcare Context?
    Khoza-Shangase K; Masondo N
    Int J Environ Res Public Health; 2020 Apr; 17(7):. PubMed ID: 32290287
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interventions for cisplatin-induced hearing loss in children and adolescents with cancer.
    Freyer DR; Brock P; Knight K; Reaman G; Cabral S; Robinson PD; Sung L
    Lancet Child Adolesc Health; 2019 Aug; 3(8):578-584. PubMed ID: 31160205
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Store-and-Forward Tele-Audiology Solution to Promote Efficient Screenings for Ototoxicity during Cisplatin Cancer Treatment.
    Dille MF; McMillan GP; Helt WJ; Konrad-Martin D; Jacobs P
    J Am Acad Audiol; 2015 Oct; 26(9):750-60. PubMed ID: 26415968
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cancer survivors treated with platinum-based chemotherapy affected by ototoxicity and the impact on quality of life: a narrative synthesis systematic review.
    Pearson SE; Taylor J; Patel P; Baguley DM
    Int J Audiol; 2019 Nov; 58(11):685-695. PubMed ID: 31545660
    [No Abstract]   [Full Text] [Related]  

  • 59. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.
    Bokemeyer C; Berger CC; Hartmann JT; Kollmannsberger C; Schmoll HJ; Kuczyk MA; Kanz L
    Br J Cancer; 1998 Apr; 77(8):1355-62. PubMed ID: 9579846
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Statistical factors associated with utilisation of ototoxicity monitoring services for multi-drug-resistant tuberculosis patients in the Western Cape.
    Ramma L; Nhokwara PT; Rogers C
    S Afr J Commun Disord; 2019 Jan; 66(1):e1-e6. PubMed ID: 30843411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.